Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 90Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 33Triple Negative Breast Neoplasms 22Squamous Cell Carcinoma of Head and Neck 19Neoplasms 18Neoplasm Metastasis 18Ovarian Neoplasms 17Stomach Neoplasms 15Lung Neoplasms 13Head and Neck Neoplasms 11Esophageal Squamous Cell Carcinoma 10Esophageal Neoplasms 10Cholangiocarcinoma 10Recurrence 9Melanoma 8Small Cell Lung Carcinoma 7Sarcoma 7Pancreatic Adenocarcinoma 7Inflammatory Breast Neoplasms 7Breast Neoplasms, Male 7Adenocarcinoma 7Prostatic Neoplasms 6Fallopian Tube Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma, Ovarian Epithelial 5Biliary Tract Neoplasms 5Uterine Cervical Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ductal, Breast 4

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Resectable Biliary Tract Cancer × Albumin-Bound Paclitaxel × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡